Can your genes predict Ozempic's success? new study targets prediabetes in Mexican-Americans
NCT ID NCT05119179
First seen Mar 18, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This study looks at how genetic differences in Mexican-Americans with prediabetes affect their response to semaglutide (Ozempic), a GLP-1 drug. Researchers will measure changes in insulin production, blood sugar, and gene activity in 300 participants. The goal is to find genetic markers that predict who benefits most, paving the way for personalized diabetes prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UTHealth Clinical Research Unit (CRU) at UT Brownsville
RECRUITINGBrownsville, Texas, 78520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Ozempic)
What this could lead to
If successful, this could help doctors predict who will benefit most from GLP-1 drugs like Ozempic, leading to more personalized treatment for prediabetes and type 2 diabetes.
What could go wrong
This is an early-stage genetic study, not a treatment trial. The findings may not lead to immediate clinical changes, and individual responses to GLP-1 drugs can vary widely.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.